医学
内科学
传统PCI
经皮冠状动脉介入治疗
心肌梗塞
心脏病学
心力衰竭
基里普班
优势比
逻辑回归
糖尿病
内分泌学
作者
Huibo Wang,Ying Yang,Ping Zeng,Rihong Huang,Xinyong Cai,Liang Shao,Liu Fu-yuan,Yuhua Lei,Dongsheng Li,Zhixing Fan,Jun Yang,Jing Zhang,Jian Yang
标识
DOI:10.31083/j.rcm2510382
摘要
The systemic immune-inflammation index (SII) is a proven, reliable inflammatory marker of the atherosclerotic process. Additionally, inflammation is one of the most important mechanisms of heart failure (HF) after myocardial infarction (MI). However, it is not clear whether SII is related to the risk of in-hospital HF in patients with MI. Thus, we aimed to explore the relationship between SII and the risk of new-onset in-hospital HF in ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (pPCI).
科研通智能强力驱动
Strongly Powered by AbleSci AI